<DOC>
	<DOCNO>NCT01356290</DOCNO>
	<brief_summary>Patients relapse medulloblastoma poor prognosis whether treated conventional chemotherapy , high-dose chemotherapy stem cell rescue , irradiation combination modality . Antiangiogenetic therapy emerge new treatment option solid malignancy . The frequent , metronomic schedule target proliferate tumor cell endothelial cell , minimize toxicity . In study investigator evaluate use biweekly intravenous bevacizumab combination five oral drug ( thalidomide , celecoxib , fenofibrate , alternate cycle daily low-dose oral etoposide cyclophosphamide ) , augment alternate course intrathecal etoposide liposomal cytarabine . The aim study extend therapy option child recurrent progressive medulloblastoma , know curative therapy exists , prolong survival maintain good quality life . The primary objective MEMMAT trial evaluate activity multidrug antiangiogenic approach heavily pretreated child young adult . Additionally , progression-free survival ( PFS ) , overall survival ( OS ) , well feasibility toxicity examine .</brief_summary>
	<brief_title>Metronomic Targeted Anti-angiogenesis Therapy Children With Recurrent/Progressive Medulloblastoma</brief_title>
	<detailed_description />
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<criteria>Relapsed progressive medulloblastoma ( least one site untreated recurrent disease ) Histological confirmation medulloblastoma diagnosis relapse Female male , age 0 &lt; 20 year ( time original diagnosis ) Participants must normal organ bone marrow function ( ALT &lt; 5x institutional upper limit normal , creatinine &lt; 1.5x institutional upper limit normal age , WBC &gt; 1000/mm3 , platelet &gt; 20,000/mm3 . Patients value less WBC 2000/mm3 platelet 50,000/mm3 require initiation treatment etoposide cyclophosphamide lower start dose define within protocol . Karnofsky performance status ≥50 . For infant child le 12 year age , Lansky play scale ≥50 % use Written informed consent patient / parent Active infection VPshunt dependency Pregnancy breast feed Conventional chemotherapy , antiangiogenic treatment complete irradiation disease current relapse ( surgery may perform antiangiogenic treatment ; patient sit disease irradiate still eligible protocol ) Known hypersensitivity drug protocol Active peptic ulcer Any significant cardiovascular disease control standard therapy e.g . systemic hypertension Anticipation need major elective surgery course study treatment Any disease condition contraindicate use study medication/treatment place patient unacceptable risk experience treatmentrelated complication Nonhealing surgical wound A bone fracture satisfactorily heal</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Medulloblastoma</keyword>
	<keyword>Relapse</keyword>
	<keyword>Children</keyword>
	<keyword>antiangiogenic</keyword>
	<keyword>metronomic</keyword>
	<keyword>intrathecal</keyword>
</DOC>